New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 11, 2014
08:09 EDTWXWuXi PharmaTech, Pacific Biomarkers announce collaboration
WuXi PharmaTech and Pacific Biomarkers announced a biomarker collaboration. In a new agreement, PBI will provide access to its extensive menu of validated biomarker assays to support WuXi's integrated clinical trial testing services. This includes bioanalysis and central laboratory services for pharmaceutical and biotech companies performing clinical drug development in China. Biomarkers from PBI complement WuXi's own biomarker capabilities. PBI has a leading position in biomarkers for cardiovascular diseases, diabetes, obesity, acute kidney injury, musculoskeletal disorders, and inflammation. WuXi offers clinical biomarker services in anatomic pathology, hematology, genomics, and soluble biomarkers focusing on oncology and infectious diseases.
News For WX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
19:20 EDTWXWuXi consortium to acquire Ambrx
A consortium consisting of entities affiliated with Fosun Pharmaceutical, HOPU Investments, CEL Healthcare Fund, and WuXi PharmaTech (WX) announced that it has signed a merger agreement to acquire Ambrx (AMBX). The transaction is expected to close in Q2. Chairman Chen Qiyu of Fosun Pharma said, "This joint acquisition will result in great synergy with [our] current R&D system and platform. Under the help of Fosun Pharma, Ambrx's business expanding in China will enable Chinese patients to get faster access to innovative therapeutic drugs." Ge Li, CEO of Wuxi, remarked, "This transaction will allow WuXi to broadly access Ambrx's best-in-class ADC platform and biologics development capabilities."

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use